Chemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, USA.
Chem Commun (Camb). 2018 May 1;54(36):4521-4524. doi: 10.1039/c8cc01154k.
Cyclin-dependent kinases have emerged as important targets for cancer therapy. HSD992, containing a novel scaffold based on the tetrahydro-3H-pyrazolo[4,3-a]phenanthridine core, inhibits CDK2/3 but not other CDKs and also potently inhibits several cancer cell lines.
细胞周期蛋白依赖性激酶已成为癌症治疗的重要靶点。HSD992 含有基于四氢-3H-吡唑并[4,3-a]菲啶核心的新型骨架，可抑制 CDK2/3，但不抑制其他 CDK，还能强烈抑制多种癌细胞系。
